VOYA Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

VOYA Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-122,504	Closed	-$13.1M	–	3050
2023 Q1	$13.1M	Buy	122,504 +51,761	+73%	+$5.96M	0.01%	641
2022 Q4	$7.78M	Buy	70,743 +18,658	+36%	+$1.21M	0.01%	813
2022 Q3	$3.07M	Buy	52,085 +40,731	+359%	+$1.86M	﹤0.01%	1157
2022 Q2	$321K	Sell	11,354 -406	-3%	-$11.8K	﹤0.01%	2129
2022 Q1	$444K	Buy	11,760 +865	+8%	+$34.2K	﹤0.01%	1986
2021 Q4	$431K	Buy	+10,895	New	+$341K	﹤0.01%	2105

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

VOYA Investment Management's RXDX Position: Q2 2023 in Review

VOYA Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 122,504 shares — an estimated $13.1M sold.

VOYA Investment Management first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $13.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

VOYA Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
VOYA Investment Management sold 122,504 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.1M.
VOYA Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
VOYA Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $13.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on VOYA Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.